Jefferies Keeps Optimer (OPTR) at Buy as CEO Makes Plans For Growth

Jefferies maintained a Buy rating on Optimer Pharmaceuticals (NASDAQ: OPTR), a company that focuses on the discovery, development and commercialization of anti-infective products, with one marketed drug for the treatment of diarrhea, DIFICID (fidaxomicin/OPT-80).

"While preannounced 3Q12 gross Dificid sales of $18.4M (~+2% q/q) are soft, OPTR's new strategy to drive further Dificid growth is reassuring," said analyst Eun K. Yang.

To address Dificid cost issues and enable patient access, Optimer Pharmaceuticals CEO offered a new strategy, including a 25 percent discount to acute care hospitals, New Technology Add-On Payment, and a Dificid Rx Assist program.

Jefferies cut its price target on Optimer to $16.00 (from $17.00) to reflect revised U.S. sales and EU royalties.

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $11.46 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Va Tech Wabag Ltd. (VATW:IN) PT Raised to INR2,410 at ICICI Securities
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating